By repurposing one of the human body's natural cargo transports, researchers from Harvard University and the University of Nebraska-Lincoln have developed a vaccine platform that could curb certain challenges of vaccines. The researchers used extracellular vesicles – nanoparticles naturally present in cells – to which viral antigens were added to their surfaces. Then, the researchers tested the extracellular vesicles on mice. Those facing the flu virus without a vaccine survived less than 30% of the time, while those given three doses of the extracellular vesicle-based vaccine survived in 60–70% of cases.
An official website of the United States government.